Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens, we used retrospective observational data to evaluate various outcomes for patients with new...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Andrew H., Perl, Alexander E., Luger, Selina M., Loren, Alison W., Gill, Saar I., Porter, David L., Babushok, Daria V., Maillard, Ivan P., Carroll, Martin P., Frey, Noelle V., Hexner, Elizabeth O., Martin, Mary Ellen, McCurdy, Shannon R., Stadtmauer, Edward A., Paralkar, Vikram R., Bruno, Ximena Jordan, Hwang, Wei-Ting, Margolis, David, Pratz , Keith W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278286/
https://www.ncbi.nlm.nih.gov/pubmed/35507945
http://dx.doi.org/10.1182/bloodadvances.2022007265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278286/
https://www.ncbi.nlm.nih.gov/pubmed/35507945
http://dx.doi.org/10.1182/bloodadvances.2022007265

Ejemplares similares